1. Introduction {#s0005}
===============

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer-related death worldwide ([@bb0005]). Nearly half of all new cases of liver cancer (50.5%) and related deaths (51.4%) are estimated to occur in China ([@bb0005]). HCC accounts for 70--80% of all liver cancers. The survival rate of patients with HCC after the onset of symptoms is generally less than one year on the late presentation of HCC at least in part due to a lack of reliable tools for early diagnosis ([@bb0005]).

Ultrasound is recommended as a screening tool for early detection of HCC. However, ultrasound is not very sensitive and is highly operator dependent ([@bb0010]). Computed tomography (CT) is not recommended as a screening tool for HCC because of the attendant radiation exposure ([@bb0010], [@bb0015]). One current focus of HCC research is the development of a blood test to aid the diagnosis of this disease. The traditional serum biomarker for HCC, α-fetoprotein (AFP) has been found to have a sensitivity of 41--65%, and a specificity of 80--90% when a cut-off value of 20 ng/ml has been used. The sensitivity was lower when AFP was used to detect early-stage HCC ([@bb0020]). Many other serologic biomarkers of HCC are available, including des-gamma carboxyprothrombin (DCP) and *Lens culinaris* agglutinin-reactive AFP (AFP-L3) ([@bb0025]), Dickkopf-1 (DKK1) ([@bb0030]), and squamous cell carcinoma antigen (SCCA) ([@bb0035]). However, these markers are insufficient for the early diagnosis of HCC ([@bb0040], [@bb0045]). Therefore, there is an urgent need for the identification of novel diagnostic markers for this purpose.

Recent studies have shown that the abnormal protein release by tumor cells can elicit humoral immune responses as self-antigen and are called tumor-associated antigens (TAAs). Unlike autoantibodies in autoimmune diseases, autoantibodies against the TAAs have been reported in a wide variety of tumors. Some have been reported to be present several months to years before manifestations of the clinical signs of tumor ([@bb0050], [@bb0055], [@bb0060]). Furthermore, magnified signals of the anti-TAA autoantibodies can be easier to detect than TAAs themselves, suggesting that the measurement of anti-TAA antibodies may have various advantages as immunodiagnostic markers ([@bb0050], [@bb0065]). Therefore, anti-TAA autoantibodies seem to have great potential value in the screening and early diagnosis of cancer. Autoantibodies against TAAs have been reported in patients with HCC, but only by a series of studies on small cohorts ([@bb0040]). Therefore, the potential value of the anti-TAAs as serum biomarkers for HCC especially for early stage HCC, is still unclear.

The aim of the present study was to use a protein microarray system for high throughput analysis ([@bb0070]) to screen for autoantibody-based serum markers for early HCC, and to evaluate the value and timing of those autoantibodies in the early diagnosis of HCC.

2. Material and Methods {#s0010}
=======================

2.1. Study Population {#s0015}
---------------------

For screening of specific TAAs for early HCC, total protein from frozen tissues of ten cases of HCC was extracted as an antigen library for serological proteome analysis (SERPA). The tumor samples were obtained from patients with hepatitis B virus (HBV)-related HCC with Barcelona Clinic Liver Cancer staging system (BCLC) stage A. The patients underwent surgical treatment at the Beijing You-An Hospital from 2011 to 2012. There were 7 men and 3 women, aged 42--62 years with a median age of 51.5 years. Serum samples for SERPA were also obtained from 10 cases of HBV-related HCC with BCLC stage A. The demographics were 7 men and 3 women, aged 43--65 years with a median age of 52.6 years. Other sera from 10 HBV-related cirrhosis patients without HCC, and 10 healthy volunteers were used as controls.

For clinical validation, a total of 914 serum samples were applied, including 295 cases of HCC, 132 cases of liver cirrhosis, 119 cases of chronic hepatitis, 103 cases of other cancers (23 colon cancer, 31 rectal cancer, 30 gastric cancer and 19 non-gastrointestinal tumor), and 265 healthy controls. Clinical characteristics of the samples are shown in [Table 1](#t0005){ref-type="table"} and supplementary Tables 1 and 2. All the samples had AFP levels measured with a commercially available electrochemiluminescence immunoassay kit (Roche, USA). Samples with an AFP value of more than 20 ng/ml were defined as AFP positive. The patients were retrospectively recruited during 2010--2013 from the Liver Research Center, Departments of Oncology, and General Surgery, Beijing Friendship Hospital, Capital Medical University, Department of Minimally Invasive Interventional Radiology, Beijing Youan Hospital, Capital Medical University and the Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Medical College of Chinese People\'s Armed Police Force. HCC diagnosis was based on ultrasound, CT, or Magnetic Resonance Imaging (MRI) characteristics and biochemistry (AFP serology and liver function enzymes), according to the American Association for the Study of Liver Diseases guidelines ([@bb0070]). Early-stage HCC was defined according to the BCLC stage 0 + A ([@bb0075]). Diagnosis of chronic hepatitis B included the presence of HBsAg more than six months, HBV DNA concentrations higher than 10^3^ copies/ml and serum alanine aminotransferase elevation, according to the guidelines of prevention and treatment of chronic HBV infection ([@bb0080]). Diagnosis of chronic hepatitis C was based on positivity for anti-HCV antibody along with HCV RNA (\> 500 IU/ml) in patients with signs of chronic hepatitis. Alcoholic hepatitis was defined by the history of alcohol abuse more than 5 years (alcohol consumption for male ≥ 40 g/day and female ≥ 20 g/day) or alcohol consumption ≥ 80 g/day within 2 weeks, elevated ALT, AST, GGT and AST/ALT \> 2 without evidence of liver dysfunction and HBV/HCV infection. Diagnosis of liver cirrhosis should meet at least one of the following three criteria: (1) Histologically confirmed of cirrhosis (Metavir F4 or Ishak 5/6); (2) clinically presentence of liver dysfunction (albumin \< 35.0 g/l, or International Normalized Ratio (INR) \> 1.3) and portal hypertension (endoscopy showing esophageal varices, or imaging showing liver surface nodularity, splenomegaly or hypersplenism); (3) chronic liver disease with development of ascites, variceal bleeding or encephalopathy. Non-liver cancer patients were pre-operative patients who had no history of liver disease. The healthy controls were eligible blood donors with normal liver biochemistry, no history of liver disease and no malignant disease. Patients with autoimmune liver disease such as autoimmune hepatitis, primary biliary cirrhosis, as well as other autoimmune diseases such as diabetes, rheumatoid arthritis, and systemic lupus erythematosus were excluded from the study.

All the samples were stored at − 80 °C until testing. The study protocol was approved by the Clinical Research Ethics Committee of Beijing Friendship Hospital, Capital Medical University. All participants provided their written informed consent to participate in this study.

2.2. SERPA Analysis for the Screening of HCC-related TAAs {#s0025}
---------------------------------------------------------

Total protein from tumor tissue was extracted as described previously ([@bb0085]). Briefly, frozen tissue was lysed in 5 μl lysis buffer (7 mol/L urea, 2 mol/L thiourea, 4% 3-\[(3-cholamidopropyl)dimethylamino\]-1-propanesulfonate (CHAPS), 1% dithiothreitol (DTT), 2% immobilized pH gradient (IPG) buffer (pH 3--10), protease inhibitor cocktail) per mg tissue, and clarified by centrifugation. After measurement of protein concentration with a 2-D Quant kit (GE Healthcare), the extracted protein was purified with a 2-D Clean-up kit (GE Healthcare). Equal parts of total proteins extracted from tumor tissue of HCC cases were mixed before use.

SERPA analyses were performed as described previously ([@bb0090]). Briefly, the first dimensional isoelectric focusing (IEF) was performed on pre-cast 18 cm immobilized pH 3--10 gradient (IPG) strips (GE Healthcare) with a total of 800 μg protein. Following IEF, the second dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed and followed by Western Blot analysis with serum samples at 1:100 dilution as the source of primary antibodies. After incubation with horseradish peroxidase (HRP) conjugated goat anti-human IgG (Invitrogen) at 1:5000 dilution, immunoreactive spots were detected using the ECL kit (Millipore) according to the manufacturer\'s instructions. The proteomic profile of proteins from the HCC tissue was used as a reference map for spot analysis. Spots on immunoblotting maps were matched to the reference map, and those detected in early HCC serum but not in liver cirrhotic or normal sera were excised for protein identification. Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) was used for identification of the selected proteins. Mascot (Matrix Science, London, UK) was used for protein identification by searching the peak lists against the International Protein Index (IPI) Human database. A protein score with a p-value less than 0.05 was considered significant.

2.3. Protein Microarray Analysis for the Clinical Validation of Screened TAAs {#s0030}
-----------------------------------------------------------------------------

Full length or fragments of recombinant proteins for selected TAAs which were available for enzyme-linked immunosorbent assay (ELISA) were purchased whenever possible. For two TAAs i.e. apoptosis-inducing factor (AIF) and heterogeneous nuclear ribonucleoprotein (hnRNP) A2, the full length recombinant proteins were prepared as described previously ([@bb0090]).

The preparation of protein microarray and the microarray detection of serum samples were performed according to our previous study ([@bb0090]). Briefly, the screened TAA proteins were diluted with an optimized individual concentration and robotically attached in ordered arrays on aldehyde-activated glass slides by a computer-controlled microchip spotting instrument (Cartesian Pixsys 3000). Human IgG (Sigma, St. Louis, MO) was used as a positive control and an internal standard for calibration of signal intensity of each test, while bovine serum albumin (Sigma) and sample liquid were used as negative controls. Microarray detection was performed with serum samples at 1:5 dilution. After incubation with rabbit anti-human IgG conjugated to HRP(sigma) at 1:8000 dilution, immunoreactive spots were detected using a chemiluminescent solution (Millipore). The signal intensities of the spots and background values were measured using array vision 7.0 (array vision, USA).

2.4. Western Blots and Immunohistochemistry Analysis for CENPF {#s0035}
--------------------------------------------------------------

For the analysis of levels of autoantibody to centromere protein F (CENPF), a recombinant N-terminal 120--220 amino acid fragment of CENPF protein with an N-terminal glutathione S-transferase (GST) tag was prepared (data not shown) as the antigen for Western Blot analysis, as described in our previous studies ([@bb0085], [@bb0090]). Briefly, Western Blot analysis was performed with antibody against GST (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:4000 dilution or serum samples at 1:250 dilution as primary antibodies. After incubation with HRP-conjugated goat anti-human IgG (Invitrogen) at 1:5000 dilution, immunoreactive spots were detected using the ECL kit (Millipore) according to the manufacturer\'s instructions.

For immunohistochemistry (IHC) analysis of CENPF, sections (4 μm thick) were cut, and after deparaffinization of the slides, endogenous peroxidase activity was blocked with 0.3% H~2~O~2~ in methanol for 30 min. Immunohistochemical staining was performed using anti-human CENPF antibody (diluted 1:100, Abcam) at 37 °C for 1 h, and visualization of antigen--antibody reactions was achieved with 3,30-diaminobenzidine (Vector SK-4100). Tissue structures were visualized by counterstaining with hematoxylin. The slides were examined separately by two independent pathologists without any prior knowledge of the patient\'s clinical and pathological parameters.

2.5. Statistical Analysis {#s0040}
-------------------------

Statistical analysis was performed with SPSS for Windows (version 19.0) and MedCalc (version 10.4.7.0). Differences between two independent groups were tested with the ANOVA. Receiver operating characteristic (ROC) curves were constructed to assess sensitivity, specificity, and respective areas under the curves (AUCs) with 95% CI to evaluate the diagnostic value of the serum markers. The optimum cutoff values for diagnosis were determined by calculating the Youden index, and the corresponding signal intensity number was set as a cutoff value for positivity of individual autoantibodies to TAAs. The correlations between autoantibody positivity in serum and clinicopathological characteristics were analyzed using the chi-squared (χ^2^) test with Yate\'s correction. We took p values lower than 0.05 (two sided) to indicate statistical significance.

3. Results {#s0050}
==========

Using an antigen library of a mixture of total proteins extracted from tumor tissue of 10 cases of early HBV related-HCC, SERPA analysis was performed for the screening of HCC-related TAAs. Mixtures of serum samples of ten early HBV-related HCC cases, ten HBV-related cirrhosis cases, and ten healthy controls were used as primary antibody for Western Blot analyses. [Supplementary Fig. 1](#f0005){ref-type="fig"}A shows a representative Coomassie blue-stained 2-DE. Different patterns of reactivity were obtained by probing with HCC serum, liver cirrhosis serum, and normal control serum, and representative immunoreactive patterns with HCC, liver cirrhosis and normal control serum are shown in [Supplementary Fig. 1](#f0005){ref-type="fig"}B--D. By comparing and matching the antigenic protein profile of each 2-D immunoblot on the original 2-DE, we identified 18 protein spots that were frequently recognized by HCC serum, but not by serum from liver cirrhosis and normal controls ([Supplementary Fig. 1](#f0005){ref-type="fig"}A). By MALDI-TOF mass spectrometry analysis, the 18 immunoreactive proteins which exhibited different frequencies of recognition were identified (Supplementary Table 3).

A total of 22 TAAs were used to make protein microarrays for high throughput clinical validation, including the 18 TAAs screened by the present study. For comparison of performance of the TAAs, we also included in the protein microarray two TAAs reported by other studies: insulin-like growth factor 2 mRNA-binding protein 2 (IMP-2) ([@bb0095]) and calreticulin (CRT) ([@bb0100]), as well as two TAAs identified by our previous study: AIF and hnRNP A2 ([@bb0090]). The recombinant proteins of the 22 TAAs applied for preparation of the protein microarray are shown in Supplementary Table 4. A schematic representation of antigen array, and the representative scan images of the protein microarray are shown in [Fig. 1](#f0015){ref-type="fig"}A and B. Western Blot analysis of three HCC sera with various levels of autoantibody to CENPF identified by the microarray detection showed consistent serum levels of autoantibody to CENPF confirming the results obtained by the microarray detection ([Fig. 1](#f0015){ref-type="fig"}C).

After microarray detection with the 914 serum samples, ROC curves were made for all 22 TAAs based on the individual signal intensity, and the results showed CENPF, 60 kDa heat shock protein (HSP60), IMP-2, protein disulfide-isomerase (PDIA1), aminoacylase-1 (ACY1), alpha-enolase (ENO1), annexin A4 (ANXA4), Ig kappa chain C region (IGKC), regucalcin (RGN), keratin, type II cytoskeletal 1 (K2C1), heat shock 70 kDa protein 6 (HSPA6) and CRT were significantly different (p \< 0.05) between HCC and all controls ([Fig. 2](#f0020){ref-type="fig"}A--B, Supplementary Table 5). Among them, the three TAAs, CENPF, HSP60 and IMP-2 showed better diagnostic value in HCC or early HCC, with AUC (area under the curve) values of 0.816, 0.750 and 0.708, or 0.826, 0.764 and 0.796 respectively ([Table 2](#t0010){ref-type="table"}), as well as significantly different signal intensities among HCC, liver cirrhosis, chronic hepatitis, healthy control, and other cancers ([Fig. 2](#f0020){ref-type="fig"}C--E). Comparison of prevalence of autoantibody positivity to CENPF and HSP60 between HCC and control cases showed significant difference in the number of case with autoantibody positivity to CENPF and HSP60 between HCC and liver cirrhosis or chronic hepatitis or healthy control (Supplementary Table 6). Analysis of the clinicopathological association showed that the prevalence of autoantibody positivity to CENPF and HSP60 was higher in HCC patients who were younger than 50 (p \< 0.05), and the prevalence of autoantibody positivity to CENPF was higher in patients with well-differentiated HCC or with Child-Pugh grade C (p \< 0.05, [Table 3](#t0015){ref-type="table"}). Notably, for all three TAAs, CENPF, HSP60 and IMP-2, the highest prevalence of autoantibody positivity was observed in HCC cases with tumor stage BCLC A, well-differentiated histology and Child-Pugh grade C ([Table 3](#t0015){ref-type="table"}), suggesting that the TAAs may be a good marker for surveillance and diagnosis of early HCC.

We compared only the diagnostic value of CENPF and HSP60 for early HCC with AFP, because the number of cases with results of IMP-2 autoantibody was insufficient. In contrast with total HCC, better performance of autoantibody to CENPF and HSP60 than AFP was shown when comparing early-HCC and all controls ([Table 4](#t0020){ref-type="table"}, [Fig. 3](#f0025){ref-type="fig"}A--D), with AUC values of 0.826, 0.764 and 0.749, respectively. However, for distinguishing early-HCC from liver cirrhosis or liver cirrhosis plus chronic hepatitis, the AUC values of autoantibody to CENPF or HSP60 were similar with that of AFP ([Table 4](#t0020){ref-type="table"}). The prevalence of autoantibody positivity to CENPF and HSP60 was significantly higher than that of AFP positivity in HCCs with tumor stage of BCLC A (p \< 0.001) (Supplementary Table 7), suggesting a higher diagnostic value of autoantibody for early HCC compared with the AFP. Specifically, 73.6% and 79.3% cases of early HCC with AFP negativity were seropositive for autoantibody to CENPF or HSP60, with AUC values of 0.828 and 0.779, respectively ([Table 5](#t0025){ref-type="table"}, [Fig. 3](#f0025){ref-type="fig"}D). These data indicated that the TAAs could be used as a complement for AFP in the diagnosis of AFP-negative early HCC to improve the detection rate. Combined autoantibody to CENPF with AFP improved the ability to distinguish HCC from all controls, with the AUC value of 0.894, or with sensitivity of 88.7% and specificity of 68.8% in the diagnosis of HCC ([Fig. 3](#f0025){ref-type="fig"}A, C); and with AUC of 0.882, or with sensitivity of 86.7% and specificity of 68.8% in the diagnosis of HCC at an early stage ([Fig. 3](#f0025){ref-type="fig"}B, D).

To explore the possible mechanism underlying the occurrence of autoantibody to CENPF in HCC, we analyzed the expression level and cellular localization of CENPF in HCC with various levels of autoantibody to CENPF. IHC analysis was performed on five HCC cases with high levels of serum autoantibody to CENPF (signal intensity more than 4000) and five HCC cases with negative serum autoantibody to CENPF (signal intensity less than 500). The results showed that in all HCC cases evaluated, CENPF was found in the cytoplasm or nucleus. However, overexpression of CENPF was observed in tumor tissue of all HCC cases with high levels of serum autoantibody to CENPF, while low or no CENPF expression was observed in the tumor tissue of all HCC cases with low levels of serum autoantibody to CENPF ([Supplementary Fig. 2](#f0010){ref-type="fig"}). The data suggest that the elevated CENPF autoantibody may have resulted from overexpression of CENPF protein.

4. Discussion {#s0055}
=============

Although there has been an increase in the number of reports of TAAs in various types of tumor including HCC ([@bb0040], [@bb0060], [@bb0065]), the potential value of autoantibodies in the early diagnosis of HCC remains unclear. The major concern is that the majority of studies initially screen small sample sizes without validation by large-scale samples. In the present study, using high throughput screening and clinical validation, we reported here a series of TAAs, which might be valuable markers for early detection of HCC.

Simultaneous clinical validation of dozens of candidate bio-markers with large-scale samples is extremely difficult. It is almost impossible to conduct large-scale screening and validation studies for specific tumor markers. The traditional techniques such as ELISA, Western Blot analysis, and radioimmunoassays which require relatively large quantities of antigen and patient samples are of limited use when performing large-scale clinical validations ([@bb0105]), especially when performing numerous simultaneous validations. In the present study, we believe that we have identified for the first time, a series of TAAs in HCC using SERPA analysis with total protein extracted from tumor tissue as antigen library. We have also validated the diagnostic value of candidate TAAs compared with that of AFP in a large cohort of early HCC. Twelve of the 22 candidate TAAs were identified with significance differences between HCC and controls. Five of the 12 screened TAAs have been reported previously in HCC or other cancers, including IMP-2 ([@bb0095]), CRT ([@bb0100]), ENO1 ([@bb0110]), CENPF ([@bb0125]), and HSP60 ([@bb0130]), whereas the other seven TAAs in HCC are reported here for the first time, to the best of our knowledge. Three TAAs, CENPF, HSP60, and IMP-2 showed promise for diagnosis of HCC and early HCC, with an AUC value of more than 0.7, a recognized standard for biomarkers, which have a promising diagnostic value in general ([@bb0030]). However, the fact that the majority of screened TAAs were identified with low value for diagnosis suggests the importance of high throughput clinical evaluation of the candidate TAAs.

As an essential nuclear protein associated with the centromere--kinetochore complex, CENPF plays a critical role in chromosome segregation during mitosis ([@bb0135]). Researchers have demonstrated that CENPF is overexpressed in a wide variety of human malignancies including HCC, and CENPF is an independent prognostic factor for HCC ([@bb0135]). A recent study has also reported detection of autoantibodies to CENPF in HCC by screening a T7 cDNA expression library ([@bb0125]). HSP60 is a chaperone with essential functions for cell physiology and survival, and has been reported to be involved in the pathogenesis of a number of cancers and some autoimmune disorders ([@bb0140]). HSP60 has also been shown to be present in a broad spectrum of cancers in both tissue and serum ([@bb0145]), and has been identified as a TAA in breast cancer, colorectal cancer and ovarian cancer ([@bb0130], [@bb0150]). The autoantibodies to CENPF and HSP60 were also identified in the present study, but unlike the results of previous studies, their diagnostic value for early HCC was demonstrated through high throughput clinical evaluation. IMP-2 and CRT have been reported as TAAs of HCC and many other types of cancer by several studies ([@bb0095], [@bb0100]), but not identified in the present study. However, the diagnostic value of IMP-2 for HCC was confirmed in the present study. Although there was a significant difference between autoantibody levels to CRT in HCC compared to controls, the AUC value was only 0.566, suggesting low diagnostic value for autoantibody to CRT. Another Ca-regulating protein, RGN for Ca-binding, also showed a statistically significant difference between HCC and controls, but with an AUC value of only 0.582 suggesting a similar diagnostic value as CRT.

So far, there has been less analysis concerning the clinicopathological association and comparison with AFP in the studies concerning anti-TAA autoantibodies in cancer ([@bb0040], [@bb0060], [@bb0065]). In the present study, clinicopathological analysis demonstrated that three TAAs, CENPF, HSP60 and IMP-2 had the highest prevalence of autoantibody positivity in HCC cases with tumor stage BCLC A, well-differentiated histology and Child-Pugh grade C. Therefore, the clinicopathological analysis in the present study implies that TAAs may have value in surveillance and diagnosis of early HCC. To date, AFP is still the main serum biomarker for HCC surveillance. However, AFP does not yield satisfactory results in the early diagnosis of HCC, particularly AFP-negative HCC. It has been reported that in small hepatic tumors, AFP expression is lower, whereas AFP expression is high in large tumors ([@bb0035]). The AFP level was approximately correlated with tumor size; 80% of small HCCs did not have increased levels of AFP. The sensitivity of AFP was 52% when the tumor diameter was \> 3 cm, but decreased to 25% for tumors \< 3 cm ([@bb0020], [@bb0035]). The present study showed that several anti-TAA autoantibodies were better than AFP for the diagnosis of early HCC when analyzed with all controls, whereas the efficacy of the TAAs was similar to AFP in distinguishing early HCC from liver cirrhosis. HCCs occur generally from liver cirrhosis. Although the specificity of CENPF (37.1%) or HSP60 (50.6%) autoantibody seemed to be relatively low for the discrimination of HCC from liver cirrhosis, with autoantibody positivity to CENPF or HSP60 in 73.6% or 79.3% of AFP negative early HCC cases (see [Table 5](#t0025){ref-type="table"}), the TAAs could be used as a complement for AFP in the diagnosis of AFP-negative early HCC to improve the detection rate of early HCC, and the combined autoantibody to TAAs with AFP could be helpful for the detection of AFP-negative early HCC. It is worthy to note that the prevalence of the above TAAs in LC patients was relatively high, suggesting their potential value in the detection of LC, and should be investigated further.

The generation of autoantibodies to TAAs is not fully understood. TAA proteins are most likely either mutated, overexpressed, post-translationally modified, misfolded, aberrantly cleaved, or aberrantly localized in tumor cells ([@bb0155]). It has been reported that HSP60 localizes mainly in the mitochondria, but in tumor cells it is also found in the cytoplasm and the cell membrane, leading to activation of autoimmune reactions ([@bb0160]). In one recent study on breast cancer with serum anti-HSP60 autoantibody, it was demonstrated that the level of expression of HSP60 was significantly higher in tumor tissues suggesting that overexpression of HSP60 may be at least one of the mechanisms of developing immunogenicity against this protein in breast cancer patients ([@bb0160]). Similarly, the present study also showed that the high titer of CENPF autoantibody in HCC serum may result from an auto-immune reaction in response to overexpression of CENPF, and may constitute one of the mechanisms for the generation of autoantibody to CENPF.

One limitation of our study is that the majority of sera were from patients with HBV-related disease and from China. Although HCV infections, as well as alcohol abuse are important causes of HCC, the effects of these factors were not studied. However, we plan to study the contributions of these factors in the future. Due to lack of availability of IMP-2 protein, IMP-2 was only studied in a small number of samples. Studies with more samples are needed. In addition, it is important to evaluate the data of TAAs before and after HCC occurrence, as well as before and after therapy. We plan to conduct another follow-up research in the future to evaluate further the efficacy of TAAs before and after HCC occurrence and the data of TAAs before and after therapy, as well as the evaluation for the accuracy of cut-off value of the TAAs by another independent cohort.

In conclusion, our data showed that autoantibodies against TAAs may be useful in the detection of HCC at early stages, and could be complementary to AFP as a screening test for HCC.

The following are the supplementary data related to this article.Supplementary Fig. 1SERPA analysis of autoantibodies in sera from HCC, liver cirrhosis and normal serum. (A) Coomassie blue-stained 2-DE of proteins isolated from HCC tissue lysates. Arrows indicate the most immunoreactive spots recognized by serum from HCC patients. (B) HCC, (C) liver cirrhosis, or (D) normal control patient sera were used as first antibodies. EasySee Western Marker was used as a loading control.Supplementary Fig. 2IHC analysis of expression level and cellular localization of CENPF in HCC with different levels of autoantibody to CENPF. A. A pair of representative HCC case with positive serum autoantibody to CENPF (signal intensity 4680). B. CENPF expression in a representative HCC case with negative serum autoantibody to CENPF (signal intensity 250). aAb: autoantibody. Original magnification: × 40.Supplementary tables.
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![Microarray detection and validation of autoantibodies in liver cirrhosis, chronic hepatitis, HCC, other cancers and normal serum. A. Schematic representation of the protein microarray for high-throughput clinical validation. (a) Design of the protein microarray. ● IgG, 1. IGKC, 2. HSP60, 3. A1AT, 4. IMP-2, 5. FIBB, 6. HSPA6, 7. ATPB, 8. Bovine serum albumin, 9. ALDH1A1, 10. PDIA1, 11. ENO1, 12. ANXA4, 13. CENPF, 14. SBP1, 15. ACY1, 16. hnRNP A2, 17. K2C1, 18. AIF, 19. CRT, 20. RGN, 21. PRDX3, 22. HINT1, 23. TBB4B, 24. Sample liquid (0.01 M PBS, pH 7.0); (b) scan images of a representative antigen array. B. Microarray detection of serum sample. Individual arrays were incubated with HCC serum (a), liver cirrhosis serum (b), chronic hepatitis serum (c), serum from other cancers (d), or normal serum (e). C. Western Blots showing a pattern of antibody titers to CENPF in HCC sera detected by the protein microarray. (a) Representative Western Blot with recombinant proteins CENPF showing reactivity of HCC sera with various levels of auto-antibody to CENPF detected by the protein microarray. The lane with "+" indicates antibody against GST used as a positive control; lane 1, a normal human serum used as negative control; lanes 2--4, three HCC positive sera 569, 462 and 635, respectively with signal intensities of 1025, 5068 and 20018 detected by the protein microarray; M. EasySee Western Marker (TransGen Biotech, Beijing). (b) Signal intensity of autoantibody against CENPF in HCC sera detected by the protein microarray. Lane 1: the normal serum sample; lanes 2--4: the three HCC positive sera 569, 462 and 635.](gr1){#f0015}

![ROC curves of the 22 TAAs in discriminating between HCC and controls and representative scatter diagram of signal intensity of CENPF, HSP60 and IMP-2. Upper panel: ROC curve for the 22 TAAs. A. 12 of the 22 TAAs with p-values \< 0.05. B. 10 of the 22 TAAs with p-values \> 0.05. Lower panel, scatter diagrams: signal intensity in early-HCC, HCC, LC, CH, HC and other cancers. C. CENPF. D. HSP60. E. IMP-2. Black horizontal lines indicate means, and error bars are SEs. ROC, receiver operating characteristic. HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HC, healthy controls.](gr2){#f0020}

![Comparison of the diagnostic value among autoantibodies to CENPF, AFP and combined autoantibody to CENPF and AFP for HCC or early HCC. Upper panel: ROC curve for autoantibodies to CENPF, AFP and combined autoantibody to CENPF and AFP to distinguish HCC (A) or early HCC (B) from controls (LC + CH + HC). Lower panel: comparison of positivity for the autoantibodies to CENPF, AFP and combined autoantibody to CENPF and AFP in HCC (C) or early-HCC (D). ROC, receiver operating characteristic. HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HC, healthy controls; aAb: autoantibody.](gr3){#f0025}

###### 

Clinical characteristics of research subjects for SERPA analysis and microarray detection.

  Variables                      SERPA analysis (n = 30)   Microarray detection (n = 914)                                                                                                                                               
  ------------------------------ ------------------------- -------------------------------- -------- -------- ------------------------------------ ------------------------------------- ------------------------------------- -------- --------
  AFP (ng/ml)                    \< 20                     6                                8        10       122                                  116                                   101                                   101      265
  20--400                        4                         2                                0        119      15                                   17                                    2                                     0        
  \> 400                         0                         0                                0        54       1                                    1                                     0                                     0        
  Age (years)                    Range                     43--65                           36--62   28--60   24--88                               31--76                                25--66                                25--90   20--66
  (Mean)                         (52.6)                    (48.3)                           (43.5)   (56.3)   (50.2)                               (43.2)                                (64.0)                                (45.8)   
  Gender                         Male                      7                                7        7        239                                  101                                   96                                    58       166
  Female                         3                         3                                3        56       31                                   23                                    45                                    99       
  HBV/HCV infection              HBV +                     10                               10       0        260                                  108                                   96                                    1        0
  HCV +                          0                         0                                0        17       15                                   13                                    2                                     0        
  HBV −/HCV −                    0                         0                                10       18       9[a](#tf0025){ref-type="table-fn"}   10[a](#tf0025){ref-type="table-fn"}   89[b](#tf0030){ref-type="table-fn"}   265      
  HBsAg                          Positive                  10                               10       0        260                                  108                                   96                                    1        0
  Negative                       0                         0                                10       35       24                                   23                                    91[b](#tf0030){ref-type="table-fn"}   265      
  ALT (U/L)                      ≤ 75                      8                                8        10       255                                  107                                   89                                    --       265
  \> 75                          2                         2                                0        40       25                                   30                                    --                                    0        
  Child-Pugh                     A                         8                                8        --       239                                  81                                    --                                    --       --
  B                              2                         2                                --       42       37                                   --                                    --                                    --       
  C                              0                         0                                --       14       11                                   --                                    --                                    --       
  Missing                        0                         0                                --       0        3                                    --                                    --                                    --       
  BCLC stage                     A                         10                               --       --       106                                  --                                    --                                    --       --
  B                              0                         --                               --       135      --                                   --                                    --                                    --       
  C                              0                         --                               --       39       --                                   --                                    --                                    --       
  D                              0                         --                               --       15       --                                   --                                    --                                    --       
  Tumor differentiation          Well                      4                                --       --       32                                   --                                    --                                    --       --
  Moderate                       6                         --                               --       77       --                                   --                                    --                                    --       
  Poor                           0                         --                               --       37       --                                   --                                    --                                    --       
  Missing                        0                         --                               --       149      --                                   --                                    --                                    --       
  Tumor size (cm)                ≤ 5                       10                               --       --       109                                  --                                    --                                    --       --
  \> 5                           0                         --                               --       184      --                                   --                                    --                                    --       
  Missing                        0                         --                               --       2        --                                   --                                    --                                    --       
  Vascular invasion/metastasis   Yes                       0                                --       --       46                                   --                                    --                                    --       --
  No                             10                        --                               --       247      --                                   --                                    --                                    --       
  Missing                        0                         --                               --       2        --                                   --                                    --                                    --       

HCC, hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer staging system; HBV +: with HBV infection; HCV +: with HCV infection; HBV −/HCV −: without HBV and HCV infection. SERPA: serological proteome analysis. --: data not available.

Alcoholic.

11 non-liver cancer cases miss the data of HBV/HCV infection.

###### 

Diagnostic value of autoantibodies to CENPF, HSP60 and IMP-2 for HCC or early-HCC.[a](#tf0020){ref-type="table-fn"}

  ---------------------------------------------------------------------------------------------------------------------------------
  aAb          Case number\     AUC value   95% CI           Cutoff value   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
               HCC/LC/CH/HC                                                                                               
  ------------ ---------------- ----------- ---------------- -------------- ----------------- ----------------- --------- ---------
  CENPF aAb                                                                                                               

   HCC         291/105/83/200   0.816       0.785 to 0.844   \> 1152        75.3              73.7              68.2      79.9

   Early-HCC   106/105/83/200   0.826       0.790 to 0.859   \> 1152        76.2              73.7              44.0      92.0

  HSP60 aAb                                                                                                               

   HCC         291/91/85/201    0.750       0.715 to 0.783   \> 3712        77.7              62.2              61.4      78.3

   Early-HCC   106/91/85/201    0.764       0.723 to 0.801   \> 3712        78.1              62.2              36.6      91.1

  IMP-2 aAb                                                                                                               

   HCC         92/99/91/65      0.708       0.656 to 0.756   \> 640         69.2              65.1              37.8      87.4

   Early-HCC   38/99/91/65      0.796       0.746 to 0.841   \> 640         81.6              65.1              25.8      96.0
  ---------------------------------------------------------------------------------------------------------------------------------

Control: liver cirrhosis + chronic hepatitis + healthy controls; aAb: autoantibody; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HC, healthy controls.

###### 

Correlation between the prevalence of autoantibody positivity and clinicopathological parameters in HCC.

  Parameters                          Prevalence of autoantibody positivity                                                                                                 
  ----------------------------------- -------------------------------------------------- ------- -------------------------------------------------- ------- --------------- -------
  Sex                                                                                                                                                                       
   Male                               180/236 (76.3%)                                    0.407   185/236 (78.4%)                                    0.538   51/75 (68.0%)   0.794
   Female                             39/55 (71.0%)                                              41/55 (74.6%)                                              11/17 (64.7%)   
  Age                                                                                                                                                                       
   \< 50                              66/78 (84.6%)[a](#tf0005){ref-type="table-fn"}     0.025   158/168 (94.1%)[a](#tf0005){ref-type="table-fn"}   0.000   20/27 (74.1%)   0.378
   ≥ 50                               153/213 (71.8%)                                            68/123 (55.3%)                                             42/65 (64.6%)   
  HBV infection                                                                                                                                                             
   HBV (+)                            198/260 (76.2%)                                    0.305   200/260 (76.9%)                                    0.380   57/83 (68.7%)   0.672
   HBV (−)                            21/31 (67.7%)                                              26/31 (8.39%)                                              5/9 (55.6%)     
  Child-Pugh                                                                                                                                                                
   A                                  172/237 (72.6%)[a](#tf0005){ref-type="table-fn"}   0.046   180/237 (76.0%)                                    0.189   48/68 (70.6%)   0.272
   B                                  34/40 (87.0%)                                              33/40 (85.2%)                                              8/16 (50.0%)    
   C                                  13/14 (92.9%)                                              13/14 (92.9%)                                              6/8 (75.0%)     
  BCLC stage                                                                                                                                                                
   A                                  80/105 (76.2%)                                     0.782   82/105 (78.1%)                                     0.894   28/38 (73.7%)   0.280
   B & C & D                          139/186 (74.7%)                                            144/186 (77.4%)                                            34/54 (63.0%)   
  Histology                                                                                                                                                                 
   Well differentiated                31/32 (96.7%)[a](#tf0005){ref-type="table-fn"}     0.003   27/32 (84.4%)                                      0.109   8/11 (72.7%)    1.000
   Moderately/poorly differentiated   82/114 (71.9%)                                             80/114 (70.2%)                                             21/31 (67.7%)   
  AFP                                                                                                                                                                       
   ≤ 20 ng/ml                         89/122 (73.0%)                                     0.173   101/122 (82.8%)                                    0.187   36/53 (67.9%)   0.768
   20--400 ng/ml                      84/115 (73.0%)                                             84/115 (73.0%)                                             24/37 (64.9%)   
   \> 400 ng/ml                       46/54 (85.2%)                                              41/54 (7.59%)                                              12/16 (75.0%)   
  Tumor size                                                                                                                                                                
   ≤ 5 cm                             83/109 (76.2%)                                     0.786   85/109 (78.0%)                                     0.920   28/38 (73.7%)   0.280
   \> 5 cm                            136/182 (74.7%)                                            141/182 (77.5%)                                            34/54 (63.0%)   
  Vascular invasion or metastasis                                                                                                                                           
   Yes                                32/46 (69.6%)                                      0.330   36/46 (78.3%)                                      0.916   5/7 (71.4%)     1.000
   No                                 187/245 (76.3%)                                            190/245 (77.6%)                                            57/86 (66.3%)   

With statistic significance. aAb: autoantibody.

###### 

Comparison of diagnostic value of CENPF or HSP60 autoantibody with AFP for Early-HCC.[a](#tf0010){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------
  aAb &AFP    Cases                       AUC\             95% CI           Sensitivity\   Specificity\
                                          value                             (%)            (%)
  ----------- --------------------------- ---------------- ---------------- -------------- --------------
  CENPF aAb   Early-HCC vs LC + HC + CH   0.826            0.790 to 0.859   76.2           73.7

  HSP60 aAb   0.764                       0.723 to 0.801   78.1             62.2           

  AFP         0.749                       0.708 to 0.786   49.5             93.3           

  CENPF aAb   Early-HCC vs LC             0.660            0.592 to 0.724   76.2           37.1

  HSP60 aAb   0.690                       0.620 to 0.754   78.1             50.6           

  AFP         0.675                       0.607 to 0.738   49.5             87.6           

  CENPF aAb   Early-HCC vs LC + CH        0.727            0.672 to 0.777   76.2           53.7

  HSP60 aAb   0.689                       0.631 to 0.742   78.1             46.0           

  AFP         0.695                       0.638 to 0.747   49.5             86.2           
  -------------------------------------------------------------------------------------------------------

aAb: autoantibody; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HC, healthy controls. The diagnostic cutoff values of AFP and aAb to CENPF and HSP60 were 20 ng/ml, and signal intensity of 1152 and 3712 respectively.

###### 

The diagnostic value of autoantibody to CENPF and HSP60 in AFP negative early-HCC.[a](#tf0015){ref-type="table-fn"}

  aAb                    Cases                       AUC value        95% CI           Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ---------------------- --------------------------- ---------------- ---------------- ----------------- ----------------- --------- ---------
  CENPF aAb              Early-HCC vs LC + HC + CH   0.828            0.790 to 0.862   73.6              73.7              27.7      95.3
  Early-HCC vs LC        0.659                       0.579 to 0.732   73.6             37.1              37.1              73.6      
  Early-HCC vs LC + CH   0.727                       0.666 to 0.782   73.6             53.7              31.0              87.8      
  HSP60 aAb              Early-HCC vs LC + HC + CH   0.779            0.737 to 0.817   79.3              62.2              22.8      95.5
  Early-HCC vs LC        0.706                       0.624 to 0.779   79.3             50.6              48.3              80.7      
  Early-HCC vs LC + CH   0.706                       0.643 to 0.765   79.3             46.0              30.7              88.0      

aAb: autoantibody; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value. The diagnostic cutoff values of aAb to CENPF and HSP60 were signal intensity of 1152 and 3712 respectively. HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis.

[^1]: These authors contribute equally to the work.
